StageZero Life Sciences, Ltd (SZLS-TSX)

StageZero Life Sciences, Ltd
30-70 East Beaver Creek Road
Richmond Hill, Ontario L4B 3B2
Phone: (855) 420-7140
www.stagezerolifesciences.com

StageZero Life Sciences, Ltd (“StageZero” or “the Company”) is a revenue-generating innovator in the liquid biopsy space, dedicated to the early detection of cancer and multiple disease states. The Company is focused on developing and commercializing proprietary blood-based diagnostic solutions to aid in the detection of cancer at the earliest possible stage. StageZero’s proprietary Sentinel Principle® technology platform is a liquid biopsy technology that uses a blood sample to detect cancer and other disease. The technology is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Thus, by conducting a minimally invasive blood draw, the Company can analyze the blood sample to detect disease-specific biomarkers that signal the possible presence of cancer. The science behind the Sentinel Principle® has led to the development of the Company’s flagship product, ColonSentry®, a blood-based test for assessing an individual’s risk for colorectal cancer (CRC). StageZero also offers diagnostics and risk stratification tests to assess the probability of having four of the most prevalent cancers: CRC, lung (EarlyCDT®-Lung), prostate (Prostate Health Index [phi]), and breast cancers (BreastSentry™). StageZero is using its Sentinel Principle® technology to develop its next generation test, Aristotle™, expected to launch in 2021. Aristotle™ is a multi-cancer panel for the simultaneous screening of 10 cancers (CRC, prostate, cervical, endometrial, breast, ovarian, liver, bladder, nasopharyngeal, and stomach cancer) from a single blood sample. The Company’s commercialization strategy aims to shorten the lengthy market-entry process of new diagnostic tests, targeting four market segments: (1) physician practices; (2) telehealth–consumer directed; (3) large healthcare systems; and (4) large employers/high risk populations.

* The Corporate Snapshot was last updated on April 9, 2020.